Comparative Long-Term Bone Safety of Therapies for Chronic HBV Infection

At 2 years into therapy, bone loss was slower with tenofovir alafenamide compared with tenofovir disoproxil fumarate.

Because treatment of hepatitis B virus (HBV) infection requires long-term viral suppression with an oral antiviral agent, safety considerations are particularly important. In two ongoing industry-funded, phase III trials comparing tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) for chronic HBV infection treatment, similar efficacy was shown over a 48-week period (NEJM JW Gastroenterol Nov 2016 and Lancet Gastroenterol Hepatol 2016; 1:185 and 196). Now, the trial investigators have assessed 96-week bone safety data.

Approximately 850 patients received TAF (25 mg daily) and 430 received TDF (300 mg daily). Bone mineral density (BMD) was assessed in the hip and spine using dual-energy x-ray absorptiometry.

At baseline, bone p…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Comparative Long-Term Bone Safety of Therapies for Chronic HBV Infection

Topics

Reviewing Author